The clinical impact of removing rectal gas on high-dose-rate brachytherapy dose distributions for gynecologic cancers

Irina Vergalasova | Ronald D. Ennis | Mutlay Sayan | Bo Liu | Ning J. Yue | Lara Hathout

Abstract

Purpose: To evaluate the impact of gas removal on bladder and rectal doses during intracavitary and interstitial high-dose-rate brachytherapy (HDRB) for gynecologic cancers.

Material and Methods: Fifteen patients treated with definitive external beam radiation followed by HDRB for gynecologic cancers for a total of 21 fractions, presented with a significant amount of rectal gas at initial CT imaging (CTGAS) after implantation. The gas was removed via rectal tubing followed by subsequent scan acquisition (CTCLINICAL), which was used for planning and treatment delivery. To assess the effect of gas removal on dosimetry, both bladder and rectum volumes were recontoured on CTGAS. In order to evaluate the clinical impact on the total Equivalent-Dose-in-2Gy-fraction (EQD2), each fraction was also replanned to maintain clinically delivered target coverage (HRCTV D90). EQD2 D2cm3 for bladder and rectum were compared between plans. The Wilcoxon signed rank test was performed to evaluate statistically significant differences for all comparisons (P < 0.05).

Results: Mean rectum and bladder Dmax, D0.1cm3, D1cm3, D2cm3, and D5cm3 were significantly different between CTGAS and CTCLINICAL. The mean percent increases on CTGAS for bladder were 12.3, 8.4, 9.9, 10.2, and 9.5% respectively and for rectum were 27.0, 19.6, 18.1, 18.5, and 19.4%, respectively. After replanning with CTGAS to maintain HRCTV D90 EQD2, bladder and rectum EQD2 D2 cm3 resulted in significantly higher doses. The mean EQD2 D2 cm3 difference was 2.4 and 4.1 Gy for bladder and rectum, revealing a higher impact of gas removal on rectal DVH.

Conclusion: Rectal gas removal resulted in statistically significant differences for both bladder and rectum. The resulting larger EQD2 D2 cm3 for bladder and rectum demonstrates that if patients were treated without removing gas, target coverage would need to be sacrificed to satisfy the rectum constraints and prevent toxicities. Therefore, this study demonstrates the importance of gas removal for gynecologic HDRB patients.

Key Words
rectal gas removal, HDR brachytherapy, gynecologic cancers
1 | PURPOSE

High-Dose-Rate brachytherapy (HDRB) plays a major role in the management of patients with gynecologic cancers. The advantages of brachytherapy for dose escalation include the rapid dose fall-off allowing the delivery of high doses to the target volume while sparing the organs at risk (OAR), mainly the rectum, bladder, sigmoid and bowel. Image-guided adaptive brachytherapy (IGABT) is now accepted as the gold standard for locally advanced cervical cancer.1 RetroEMBRACE II has established new dose constraints for OARs. The High-Risk Clinical Target Volume (HRCTV) D90 EQD2 has been increased to >90 Gy using $\alpha/\beta = 10$, while the planning aims for bladder D2cm$^3$ EQD2 and rectum D2cm$^3$ EQD2 using $\alpha/\beta = 3$ have been lowered to <80 and <65 Gy, respectively.2 Indeed, it has been shown that there is a linear correlation between the D2cm$^3$ received by the OARs with complication rates.3 In order to meet these more challenging constraints, appropriate placement of applicators and dwell time optimization are crucial. In addition, dosimetry can be affected by the filling status of the rectum and bladder. The effect of bladder distension on dose received by OARs has been previously reported and while various filling protocols have been suggested,4-9 no clear consensus has been reached. Since rectal dose is the hardest constraint to meet, beginning in the summer of 2019, our group has implemented the routine use of a rectal tube for removal of gas. The goal of this study is to evaluate the effects of gas removal on rectal doses during intracavitary and interstitial HDRB for gynecologic cancers.

2 | MATERIALS AND METHODS

In this retrospective IRB-approved study, patients with gynecologic cancers treated with definitive EBRT followed by intracavitary or interstitial brachytherapy boost were reviewed. Patients with a significant amount of gas at the time of CT simulation requiring gas removal after insertion of HDRB applicators were eligible. No formal policy regarding rectal filling at the time of brachytherapy existed in our department at the time of study. However, gas removal using a rectal tube was often used at the discretion of the treating radiation oncologist. Interstitial applicator insertion was performed in the operating room under general and epidural anesthesia, whereas intracavitary applicator insertion was performed on an outpatient basis with PO pain medication. All patients had a Foley catheter inserted during the procedure. Tandem and ovoid applicators were used for intracavitary HDRB while a template, cylinder and interstitial needles were used for interstitial brachytherapy. Each patient was scanned on the same departmental GE Lightspeed 16 CT simulation scanner (GE Healthcare, Chicago, IL, USA) with 1.25 mm axial image slices. The images were obtained with the patient in the supine position with arms on the chest and legs in a neutral position. The images were reviewed with the treating physician and in the event of a rectal diameter >4cm in the region proximal to the HRCTV (i.e., denoting the presence of significant gas), a rectal tube was inserted and the patient underwent a second CT simulation with the rectal tube in place. The rescanned image without gas (CT CLINICAL) was the one used clinically for planning and treatment delivery. The CT images were transferred to the treatment planning system Eclipse v.15.3 (Varian Medical Systems; Palo Alto, CA, USA) and image registration with diagnostic $T_2$ MRI sequence was performed for better target volume delineation. The High-Risk Clinical Target Volume (HRCTV), bladder, rectum, sigmoid, and bowel were contoured by the treating radiation oncologist following the GEC-ESTRO working group guidelines.3 The prescribed HDRB boost doses ranged between 25 and 30 Gy delivered in 4-5 fractions. Total equivalent dose in 2Gy-fraction (EQD2) was calculated for all fractions using the linear quadratic model with an $\alpha/\beta = 3$ for OARs and $\alpha/\beta = 10$ for tumor. All patients were planned with the goal of satisfying the EMBRACE II dose constraints.5 Plans were calculated using geometric, volume and manual optimization techniques in BrachyVision. HDRB was delivered with the Varisource iX afterloader (Varian Medical Systems; Palo Alto, CA, USA).

In order to evaluate the impact of gas on rectal and HRCTV dose constraints, the clinically used CT without gas (CT CLINICAL) was then registered to the initial CT with gas (CT GAS) for each appropriate fraction. The HRCTV was transferred onto the CT GAS scan via image registration. Given the differences in rectal and bladder filling between the two CTs, rectum and bladder organ volumes were recontoured by the same physician on the CT GAS scan. Dosimetric parameters were then extracted from the clinical plan on the newly contoured rectum and bladder volumes from CT GAS for comparison. The following metrics were tabulated per scan: the maximum dose to the rectum ($D_{\text{max}}$ Rectum), the highest cumulative dose delivered to 0.1 cm$^3$ of the rectum ($D_{0.1}\text{cm}^3$ Rectum), the highest cumulative dose delivered to 1.0 cm$^3$ of the rectum ($D_{1}\text{cm}^3$ Rectum), the highest cumulative dose delivered to 2.0 cm$^3$ of the rectum ($D_{2}\text{cm}^3$ Rectum), and the highest cumulative dose delivered to

| D0.1cm$^3$ bladder | 559.7 ± 102.2 | 606.8 ± 123.2 | 0.021 |
| D1 cm$^3$ bladder | 4520 ± 85.7 | 4966 ± 89.6 | 0.007 |
| D2 cm$^3$ bladder | 4127 ± 78.9 | 4546 ± 80.2 | 0.005 |
| D5 cm$^3$ bladder | 3503 ± 69.4 | 3835 ± 68.2 | 0.008 |
| Dmax rectum | 551.2 ± 79.4 | 700.0 ± 192.6 | 0.0003 |
| D0.1 cm$^3$ rectum | 465.4 ± 62.5 | 556.8 ± 120.0 | 0.0006 |
| D1 cm$^3$ rectum | 384.5 ± 58.9 | 454.1 ± 84.5 | <0.0001 |
| D2 cm$^3$ rectum | 347.0 ± 57.5 | 411.2 ± 76.4 | 0.0001 |
| D5 cm$^3$ rectum | 285.7 ± 55.7 | 341.2 ± 67.6 | <0.0001 |
**Bladder Dosimetric Comparison**

**FIG. 1.** Box plot comparisons of extracted dosimetric parameters for Bladder between the initial CT scan with gas (CT\textsubscript{GAS}) and the CT scan after gas removal (CT\textsubscript{CLINICAL}), which was used for clinical treatment planning and delivery.

**Rectum Dosimetric Comparison**

**FIG. 2.** Box plot comparisons of extracted dosimetric parameters for Rectum between the initial CT scan with gas (CT\textsubscript{GAS}) and the CT scan after gas removal (CT\textsubscript{CLINICAL}), which was used for clinical treatment planning and delivery.
5.0 cm³ of the rectum (D5.0 cm³ Rectum). The same parameters were also extracted for the bladder from both scans, with and without gas: Dmax Bladder, D0.1 cm³ Bladder, D1.0 cm³ Bladder, D2.0 cm³ Bladder, and D5.0 cm³ Bladder. The dose to 90% of the HRCTV volume was also recorded for this patient population, as a percentage relative to the prescribed dose (HRCTV D90%). Statistical evaluation was performed with JMP Pro 14 (SAS Institute, Cary, North CA, USA). The Wilcoxon Signed Rank test with a significance level of \( P < 0.05 \) was selected.

In order to assess the overall clinical significance of gas removal with a rectal tube, each HDRB fraction was retrospectively replanned on the CTGAS scan with the intent of achieving the same total EQD2 for HRCTV D90, as achieved by the clinically delivered course of brachytherapy. To reduce bias, a separate experienced planner generated plans using the CTGAS scan for all 21 fractions. If a single patient had multiple fractions with gas, all fractions were replanned and tabulated to calculate the total EQD2 for HRCTV D90, EQD2 Rectum D2cm³ and EQD2 Bladder D2cm³. The replanned total EQD2 for OARs and HRCTV was then compared to the clinically delivered EQD2 for each of the three aforementioned parameters, per included patient. Statistical evaluation was again performed with the Wilcoxon Signed Rank test with a significance level of \( P < 0.05 \).

### 3 | RESULTS

Between June 2019 and April 2020, fifteen patients treated with definitive EBRT followed by HDRB for gynecologic cancers for a total of twenty-one fractions of HDRB were included in this retrospective IRB-approved study. The median age at the time of treatment of the patient dataset was 59 (interquartile range (IQR): 47.5–64). Eleven patients were diagnosed with cervical cancer, three patients with vaginal cancers and one patient with medically inoperable endometrial cancer. All patients received 45Gy external beam radiation in 25 fractions, prior to brachytherapy boost regimens. Interstitial HDRB was performed in 10 patients using tandem, cylinder and needles (ranging from 6 to 20) while five patients underwent intracavitary brachytherapy with tandem and ovoid applicators.

The mean HRCTV D90 and HRCTV V100 achieved for the 21 clinically delivered fractions was 103.1% and 91.9%, respectively. This indicates that all plans satisfied EMBRACE II guidelines. The mean values for the extracted dosimetric comparison between all aforementioned parameters for bladder and rectum volumes extracted from both CTCLINICAL and CTGAS scans across the 21 fractions were analyzed. The mean Rectum and Bladder Dmax, D0.1cm³, D1cm³, D2cm³ and D5cm³ were significantly lower after gas removal as shown in Table 1. The mean increase in dose to the bladder on the CTGAS scan for the parameters of Dmax, D0.1cm³, D1cm³, D2cm³, and D5cm³ were as follows: 90.8, 47.1, 44.7, 41.9, and 33.3 cGy. Relative to the clinically delivered plan, these absolute

| Table 2 | Mean and standard deviation values listed for total EQD2 values for HRCTV D90, D2cm³ Bladder and D2cm³ Rectum across all studied 15 patients on both the clinically delivered plan (CTCLINICAL), as well as the replans on the initial CT scan with gas (CTGAS). Wilcoxon signed rank P-value results for each comparison are also listed. |
|----|----|----|----|
| EQD2 HRCTV D90 | CTCLINICAL Mean ± std (Gy) | 82.8 ± 5.26 | CTGAS Mean ± std (Gy) | 82.9 ± 5.23 | P-value | 0.64 |
| EQD2 D2cm³ Bladder | CTCLINICAL Mean ± std (Gy) | 71.4 ± 7.10 | CTGAS Mean ± std (Gy) | 73.5 ± 5.87 | P-value | 0.043 |
| EQD2 D2cm³ Rectum | CTCLINICAL Mean ± std (Gy) | 64.5 ± 3.35 | CTGAS Mean ± std (Gy) | 68.6 ± 5.75 | P-value | <0.0001 |

**Fig. 3.** Total EQD2 values for HRCTV D90, D2cm³ Bladder and D2cm³ Rectum of each of the 15 patients on both the clinically delivered plan (CTCLINICAL), as well as the replans on the initial CT scan with gas (CTGAS).
values correspond to mean percentage increases of 12.3, 8.4, 9.9, 10.2, and 9.5% respectively. The mean increase seen in rectal doses was even larger with $D_{\text{max}}$, $D_{0.1\text{cm}^3}$, $D_{1\text{cm}^3}$, $D_{2\text{cm}^3}$, and $D_{5\text{cm}^3}$ increasing by 148.8 cGy, 91.4cGy, 69.6, 64.2, and 55.5 cGy, respectively. In relative terms, the mean increases reported to the rectum were 27.0, 19.6, 18.1, 18.5, and 19.4%, respectively. The dosimetric impact was approximately twice as large for the rectum than the bladder. Figures 1 and 2 display these changes in dosimetric data as box plots for the bladder and rectum comparisons, respectively. The differences in box plot comparisons are especially striking for the rectum volumes in Fig. 2. It is evident that all of the dosimetric parameters extracted from the CTGAS scan have higher means and medians than those from the CTCLINICAL scan, both for bladder and rectum.

The means for the total EQD2 values of the HRCTV D90, $D_{2\text{cm}^3}$ Bladder, and $D_{2\text{cm}^3}$ Rectum, comparing the clinically delivered plans versus the replans on the CTGAS scan for the studied 15 patients are reported in Table 2. Since the intent of the replan was to maintain the same total HRCTV D90 EQD2, it is unsurprising that the comparison between those two datasets was not statistically significant ($P = 0.64$). However, the EQD2 $D_{2\text{cm}^3}$ Bladder and Rectum comparisons were both significantly different between the two datasets. The replans on CTGAS resulted in higher total EQD2 of 2.1 Gy for the Bladder $D_{2\text{cm}^3}$ and 4.1 Gy for the Rectum $D_{2\text{cm}^3}$. A point-by-point comparison for each of these EQD2 parameters per studied patient, numbered 1 through 15 was plotted to report the differences between the CTGAS replan and the clinical plan (CTCLINICAL), as shown in Fig. 3. The top plot reiterates the equivalence of HRCTV D90 target coverage for the replan with the clinical plan. Figure 3 also makes evident that for almost every single patient for $D_{2\text{cm}^3}$ Rectum, the CTGAS replan(s) resulted in larger values than for the CTCLINICAL plans to achieve the same HRCTV D90. The $D_{2\text{cm}^3}$ Bladder data points are more mixed, with about half demonstrating higher values on the CTGAS replan(s) and the rest mostly the same or slightly less than the clinically delivered plans.

Both an intracavitary and interstitial HDRB patient case are each presented in Fig. 4. The CT images shown are the CTGAS scan. The rectum contour from the clinically delivered scan (CTCLINICAL) was

**Fig. 4.** Rectum contours in different colors from CTCLINICAL and CTGAS shown for comparison on the CTGAS images for both an intracavitary (top row) and interstitial (bottom row) HDRB sample patients.
propagated onto this scan and simultaneously overlaid with the CT\textsubscript{GAS} rectum contour for comparison, in different colors. This figure demonstrates the significant increase in rectal gas between the two scans, as well as visualizes the increased proximity of the rectum to the HRCTV due to this gas. This inevitably challenges the ability to satisfy both the target and OAR constraints simultaneously.

4 | DISCUSSION

The American Brachytherapy Society suggests rectal tube insertion with or without diluted barium contrast for gas removal and better visualization of the anterior rectal wall prior to the applicator placement or at the end of the procedure. In the Embrace II protocol, bowel preparation is performed to ensure an empty rectum and sigmoid, especially when interstitial needles are used. Although guidelines recommend fleet enemas prior to brachytherapy, this has not been widely adopted across all institutions mainly because of the risk of dehydration and electrolyte disturbances due to radiation-induced diarrhea. The usefulness of fleet rectal enemas on HDR intracavitary brachytherapy was assessed in a prospective trial including 20 patients. The authors did not report differences in rectal volume and DVH constraints between fractions with and without rectal enemas. The same authors evaluated the effect of rectal enemas on rectal dosimetry after HDR vaginal cuff brachytherapy and found similar findings: rectal enemas did not impact rectum DVH and 35.6% of patients had larger rectums after enemas. To our knowledge, this is the first study to report the usefulness of rectal gas removal prior to intracavitary and interstitial HDRB for gynecologic cancers. In our study, rectal gas removal resulted in lower Bladder and Rectum mean D\textsubscript{max}, D0.1cm\textsuperscript{3}, D1cm\textsuperscript{3}, D2cm\textsuperscript{3}, and D5cm\textsuperscript{3}. In order to assess the effect of rectal gas removal on dosimetry, replanning on CT\textsubscript{GAS} was performed with the goal of achieving the same HRCTV D90 EQD\textsubscript{2}, as delivered with the CT\textsubscript{CLINICAL}. Bladder and rectum EQD\textsubscript{2} D2cm\textsuperscript{3} were significantly higher upon replanning using the CT\textsubscript{GAS}, highlighting the positive impact of rectal tube insertion for gas removal. Although the benefit was significant for both rectal and bladder DVH, gas removal was mostly advantageous for rectal dosimetry as depicted in Fig. 3.

Rectal distension has been shown to correlate with rectal DVH. Lim et al. evaluated 97 intracavitary brachytherapy implants for 51 patients with locally advanced cervical cancer and reported the impact of the tandem angle and rectal distension on rectal DVH. The authors reported an increased rectal D2cm\textsuperscript{3} of 6.58Gy with each additional centimeter of distention, however the tandem angle did not correlate with rectal dose. Merrick et al. reported similar findings for prostate brachytherapy. The mean dose to the rectal wall was increased by a factor of 1.5 in the distended state. The use of rectal tube for gas removal during vaginal cuff brachytherapy was evaluated by Sabater et al. The rectal volume significantly decreased after gas removal, which translated into a significant reduction in rectum D1cm\textsuperscript{3}, D2cm\textsuperscript{3} and D5cm\textsuperscript{3}. Despite the strong impact of gas removal on rectal and bladder DVH, our study has limitations: the retrospective nature of the study with inherent selection bias as well as the small number of patients. Furthermore, we did not evaluate the mean rectal volume since it varies from fraction to fraction depending on the contours. Unlike EBRT, for brachytherapy, only the hottest D2cm\textsuperscript{3} is reported, which is highest near the HRCTV. Therefore, the entire rectum as defined by Radiation Therapy Oncology Group from the anus to the sigmoid reflection is not routinely contoured. In order to assess the impact of gas on rectal DVH, replanning on CT\textsubscript{GAS} demonstrated the usefulness of gas removal since higher doses to bladder and rectum needed to be delivered to achieve the same HRCTV D90 EQD\textsubscript{2}.

Given the significant differences demonstrated by our results, we have clinically employed a threshold of 4 cm for the rectal diameter as an indication for rectal tube placement for interstitial and intracavitary HDRB patients. We plan on conducting future studies with a larger variety of patients and HDR brachytherapy procedures in order to more broadly investigate the impact of rectal gas.

5 | CONCLUSIONS

High HRCTV D90 while sparing the rectum, bladder and sigmoid, using the GEC-ESTRO and Embrace II guidelines requires image-guided HDRB. The rectum is usually the limiting organ-at-risk with the tightest DVH constraints. Gas removal using a rectal tube is easy, inexpensive, minimally invasive and is performed on a case-to-case basis. It reduces the rectal and bladder doses thereby allowing optimal dosimetry without sacrificing coverage of the HRCTV for intracavitary and interstitial HDR brachytherapy for gynecologic cancers.

ACKNOWLEDGMENT

IV and LH designed the study, performed experiments, data collection, and analysis. IV drafted the manuscript with assistance from LH, RE, MS, BL, and NJY all contributed substantially to the concept, design of the study and preparation of the manuscript.

REFERENCES

1. Haie-Meder C, Pötter R, Van Limbergen E et al Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiat Oncol. 2005;74:235–245.
2. Pötter R, Tanderup K, Kirisits C et al The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol. 2018;9:48–60.
3. Pötter R, Haie-Meder C, Limbergen EV et al Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol. 2006;78:67–77.
4. Cengiz M, Gürdalli S, Selek U et al Effect of bladder distension on dose distribution of intracavitary brachytherapy for cervical cancer: three-dimensional computed tomography plan evaluation. Int J Radiat Oncol Biol Phys. 2008;70:464–468.
5. Stewart AJ, Cormack RA, Lee H et al Prospective clinical trial of bladder filling and three-dimensional dosimetry in high-dose-rate vaginal cuff brachytherapy. Int J Radiat Oncol Biol Phys. 2008;72:843–848.
6. Sun L-M, Huang H-Y, Huang E-Y et al A prospective study to assess the bladder distension effects on dosimetry in intracavitary brachytherapy of cervical cancer via computed tomography-assisted techniques. Radiother Oncol. 2005;77:77–82.
7. Yamashita H, Nakagawa K, Okuma K et al Correlation between bladder volume and irradiated dose of small bowel in CT-based planning of intracavitary brachytherapy for cervical cancer. Jpn J Clin Oncol. 2012;42:302–308.
8. Sharma AD, Poddar J, K US et al Dosimetric analysis of the effects of the bladder volume on organs at risk (OAR) in high-dose-rate intracavitary brachytherapy in carcinoma cervix – an institutional study. J Contemp Brachytherapy. 2018;10:26–31.
9. Siavashpour Z, Aghamiri MR, Jaberi R, Manshadi HR, Ghaderi R, Kirisits C. Optimum organ volume ranges for organs at risk dose in cervical cancer intracavitary brachytherapy. J Contemp Brachytherapy. 2016;8:135–142.
10. Viswanathan AN, Thomadsen B. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy. 2012;11:33–46.
11. Andres I, Gutierrez-Perez M, Rodriguez-Vela MP et al The usefulness of fleet rectal enemas on high-dose-rate intracavitary cervical cancer brachytherapy. A prospective trial. J Contemp Brachytherapy. 2017;9:224–229.
12. Sabater S, Andrés I, Gascon M et al Effect of rectal enemas on rectal dosimetric parameters during high-dose-rate vaginal cuff brachytherapy: a prospective trial. Strahlenther Onkol. 2016;192:248–253.
13. Lim J, Durbin-Johnson B, Valicenti R et al The impact of maximum rectal distention and tandem angle on rectal dose delivered in 3D planned gynecologic high dose-rate brachytherapy. Int J Gynecol Cancer. 2013;23:1078–1083.
14. Sabater S, Arenas M, Berenguer R et al Dosimetric analysis of rectal filling on rectal doses during vaginal cuff brachytherapy. Brachytherapy. 2015;14:458–463.
15. Sabater S, Sevillano M, Andres I et al Reduction of rectal doses by removal of gas in the rectum during vaginal cuff brachytherapy. Strahlenther Onkol. 2013;189:951–956.
16. Merrick GS, Butler WM, Dorsey AT, Dorsey JT 3rd. The effect of constipation on rectal dosimetry following prostate brachytherapy. Med Dosim. 2000;25:237–241.